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Abstract
Background: Few drugs are available for soil-transmitted helminthiasis (STH); the benzimidazoles albendazole and
mebendazole are the only drugs being used for preventive chemotherapy as they can be given in one single dose with no
weight adjustment. While generally safe and effective in reducing intensity of infection, they are contra-indicated in first-
trimester pregnancy and have suboptimal efficacy against Trichuris trichiura. In addition, drug resistance is a threat. It is
therefore important to find alternatives.
Methodology: We searched the literature and the animal health marketed products and pipeline for potential drug
development candidates. Recently registered veterinary products offer advantages in that they have undergone extensive
and rigorous animal testing, thus reducing the risk, cost and time to approval for human trials. For selected compounds, we
retrieved and summarised publicly available information (through US Freedom of Information (FoI) statements, European
Public Assessment Reports (EPAR) and published literature). Concomitantly, we developed a target product profile (TPP)
against which the products were compared.
Principal Findings: The paper summarizes the general findings including various classes of compounds, and more specific
information on two veterinary anthelmintics (monepantel, emodepside) and nitazoxanide, an antiprotozoal drug, compiled
from the EMA EPAR and FDA registration files.
Conclusions/Significance: Few of the compounds already approved for use in human or animal medicine qualify for
development track decision. Fast-tracking to approval for human studies may be possible for veterinary compounds like
emodepside and monepantel, but additional information remains to be acquired before an informed decision can be made.
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Introduction
Soil-transmitted helminthiasis (STH) is caused primarily by four
species of nematode worms, Ancylostoma duodenale and Necator
americanus (hookworms), Ascaris lumbricoides (roundworm), and
Trichuris trichiura (whipworm), that parasitize the human gastroin-
testinal tract [1]. Some 2–3 billion people are thought to have
active infections and billions more are at risk of infection [2–4].
STH is estimated to be responsible for the loss of 39 million
disability adjusted life years (DALYs) annually [2] but the burden
of disease is currently being re-evaluated [5].
There are only four drugs recommended by the World Health
Organization (WHO) for STH, and they have been in use for
several decades: the two benzimidazole carbamates (BZs) alben-
dazole and mebendazole, levamisole, and pyrantel pamoate
[6,7]. While STH related morbidity can be controlled through
chemotherapy, various problems need to be faced as anthelmintics
are increasingly deployed in mass drug administration (MDA)
programs [6]. For practical reasons MDA requires a single drug
administration to all subjects without prior diagnosis or checking
for contra-indications.
For this reason, the BZs are preferred over levamisole and
pyrantel (which require weight-based dosing and are also
intrinsically less potent). However, the BZs are not perfect drugs
either: first, the efficacy against some of the STHs (especially T.
trichiura) is suboptimal when delivered as a single dose [8]; second
the BZs are contra-indicated in early pregnancy, which may go
unnoticed or unreported in the first trimester; and finally, the
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parasites to selective pressure potentially leading to resistance,
which has already occurred widely in veterinary practice [9,10].
Therefore, there is a pressing need for concerted efforts to discover
and develop the next generation of anthelmintic drugs and for
drug combinations. The main drivers are risk of emerging BZ
resistance, the limited spectrum of activity and the contraindica-
tions of the current drugs.
Discovering and developing new drugs (Research & Develop-
ment, R&D) is a complicated, expensive, risky and time-consuming
endeavour. For a new drug to be granted marketing authorization
in humans, it must be developed following strict regulatory
requirements [11]. Clinical development is also the most expensive
part of R&D [11]. Therefore, the decision to move a compound
from the discovery into the development stage must be carefully
considered and based on sound science and cost considerations.
Our goal is to identify and evaluate potential development
candidates for STHs to assess whether all data required to inform
the decision to initiate development are available or what
additional data are needed. Compounds registered for veterinary
medical use by the US Food and Drug Administration (FDA),
European Medicines Agency (EMA) and other regulatory bodies
have extensive safety, pharmacokinetics (in some cases) and
efficacy data derived in animals. Therefore, these should have
the potential for accelerated transition into human use.
Almost all products currently available for human helminth
diseases have been transitioned from veterinary/animal health
companies since the 1950’s [7,12]. The average transition time
was 3 years, but for older veterinary drugs, this was longer because
of the need to conduct additional studies (e.g. safety, pharmacol-
ogy) to satisfy modern requirements.
Modern rules for veterinary medicine licensure means that data
available now are essentially equivalent to those required for
human medicines; therefore transitioning can be achieved earlier.
However, criteria for veterinary medicine anthelmintic efficacy are
much more stringent than current human requirements, e.g.
generally require an efficacy defined as 90% or greater clearance
of the target organism [12,13].
The underlying approach for this analysis was first to assess
candidates based on publicly available information (through US
Freedom of Information (FoI) statements, European Public
Assessment Reports (EPAR), scientific meetings, publications,
patents, etc) that could be summarized and shared. For the
compounds that emerge as promising from this initial assessment,
further information will be sought by directly contacting the
relevant data owner for additional confidential data as appropri-
ate. This will allow identification and analysis of the missing
elements to permit an informed decision to be made on taking the
compound forward and for planning the additional experiments
that are required for human registration.
This paper summarizes the general findings and more specific
information on two veterinary anthelmintics (monepantel, emo-
depside) and on nitazoxanide, a licensed antiprotozoal drug with
evidence for anthelminthic activity, compiled from an analysis of
publicly available information in the EMA EPAR and FDA
registration files. Complete reviews with these data are provided as
supplementary data (see below). None of these has been assessed
for STH from a human drug development perspective. These
summaries are made available to help define and stimulate
decisions by potential researchers and drug developers, identify
additional investigations that may be needed for an informed
decision, as well as creating development partnerships.
Materials and Methods
Search strategy
Two searches were performed in parallel:
a. We searched PubMed (http://www.ncbi.nlm.nih.gov) up to
March 1, 2010 and contacted experts to identify potential drug
development candidates for treating infections with soil
transmitted helminths. For the electronic search the terms
‘‘chemotherapy’’, ‘‘drug’’ or ‘‘anthelmintic’’, in combination
with ‘‘in vivo’’ and ‘‘ascariasis’’, ‘‘Ascaris lumbricoides’’, ‘‘hook-
worm’’, ‘‘Ancylostoma duodenale’’, ‘‘Necator americanus’’, ‘‘trichuri-
asis’’, ‘‘Trichuris trichiura’’, ‘‘soil-transmitted helminths’’, ‘‘soil-
transmitted helminthiases’’, or ‘‘nematode’’ were used. The
search was restricted to publications over the past 20 years.
b. Marketed veterinary drugs (U.S. and/or ex-U.S.) were also
examined and categorized by the various chemical classes.
Documents reviewed for this exercise included the U.S. FoI
statements prepared by the veterinary drug companies and
approved by the FDA, EMEA and other ex-U.S. regulatory
body registration files, company product information, patents,
scientific meeting abstracts and published literature and
knowledge gathered by one of the authors (JNC) over 30
years in the animal health drug industry.
Assessment criteria
T h ec a n d i d a t ec o m p o u n d sf o rt h es e a r c h e sw e r ea s s e s s e da g a i n s ta
product profile that had been previously generated following
discussions at several meetings of experts at WHO and elsewhere
(see proposed target product profile (TPP) which is provided in detail
in Appendix S1). The assessment criteria used for the analysis contain
the key points of the TPP and required the drug to be potentially:
1. Safe for mass drug administration (MDA)
– as well tolerated as in-use BZs albendazole and mebendazole
– ideally capable of being given to pregnant women (ensuring
maximum use in affected populations)
Author Summary
There are few drugs - none ideal - for the treatment and
control of gastrointestinal helminths (soil-transmitted
nematodes) which, as chronic infections jeopardize chil-
dren’s growth, learning and ultimately individual, commu-
nity and country development. Drugs for helminths are
not attractive in human medicine, but are lucrative in
animal health. Traditionally, investment in veterinary
medicines has benefited humans for these diseases. With
modern regulations an approved veterinary medicine can
be tested in humans with little adaptation, reducing time
and cost of development. We searched for products that
could easily be transitioned into humans, having the
necessary characteristics for use in communities exposed
to these infections. A limited number of candidates met
the main criteria for selection. We provide here a detailed
analysis of two veterinary products, emodepside and
monepantel, and nitazoxanide, which is approved for
human use. In addition we include a less detailed analysis
of all products examined, and the criteria on which the
analysis was based. It is clear that the pipeline of easily
obtainable human anthelminthics remains extremely
limited, and further efforts are needed to find replace-
ments for the inadequate number of products available
today.
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3. Achieving desired effect in a single dose (maximum two doses
in one day)
4. Simple to dose (not requiring complex measurements to deliver
the drug)
5. And additionally:
– Spectrum to cover A. lumbricoides, both N. americanus and A.
duodenale, T. trichiura (and also possibly S. stercoralis)
– Minimally or not absorbed (if significantly absorbed, safety
margins must be high)
– No cross-resistance to existing drugs
To identify compounds amenable to rapid development, we
aimed for compounds that are already in human or veterinary use
or that had gone through extensive animal testing in their
development as veterinary drugs.
Results
Searches and assessment of potential drug candidates
identified
The electronic search on PubMed yielded 299 hits. After
discarding duplicate publications and studies outside our scope
(e.g. molecular papers) and veterinary drugs (as these were already
identified in our parallel search as described below), 25 potential
drug candidates remained. The majority of these were natural
product compounds and with the exception of tribendimidine,
none of these had undergone extensive animal testing, and hence
were not considered further. Through expert consultation an
additional compound was identified (nitazoxanide).
In addition, we identified several primary anthelmintics used in
veterinary medicine today. These include various representatives
from the macrocyclic lactones (MLs, avermectins and milbemy-
cins, including some experimental compounds that did not reach
the market), BZs, depsipeptides, paraherquamides, hexahydropyr-
azines, tetrahydropyrimidines, imidathiazoles, amino-acetonitriles,
salicylanilides, phenylsulfonamides, biphenylsulfides and miscella-
neous compounds. Although there are some compounds (e.g.
phenothiazines) that have been used in veterinary medicine, these
are very old drugs and were not thought to be worth including
here. A representative of each class is summarized in Table 1;
details are provided in Appendix S2. Additional details on
approved animal health compounds identified, including com-
pound class, generic name, chemical structure, current supplier,
patent approval, U.S. approval, mode of action, more specifics on
parasite claims and efficacy/resistance, dose rates, more on safety
and toxicity issues and an overall assessment of current use in
veterinary medicine.
We did not further consider the avermectin class (which
comprise a large number of animal health registered compounds,
such as doramectin, eprinomectin, ivermectin and selamectin and
agrochemical-registered compounds such as abamectin and
emamectin) to be potentially interesting drug development
candidates, as these drugs would likely be cross resistant to
ivermectin-resistant parasites. In addition, ivermectin is charac-
terized by low efficacy against hookworms [14,15]. The afore-
mentioned compounds are all very similar structurally and act by
the same mode of action, and therefore are unlikely to offer a clear
advantage over ivermectin in terms of efficacy or resistance. No
further search was undertaken for moxidectin, a milbemycin
macrocyclic lactone, as this drug is under development for
systemic helminths (onchocerciasis) in humans. The physico-
chemical characteristics of this molecule result in pharmacokinetic
advantages over ivermectin (longer residence time, larger volume
of distribution). Though milbemycin oxime, another compound in
this class, was effective in the treatment of ascarids and hookworms
in naturally infected cats [16] and in dogs (InterceptorH product
label) and is approved for Trichuris vulpis in dogs (InterceptorH
product label), only moderate egg reduction rates were observed in
baboons infected with T. trichiura [17]. Further, this compound is
only registered for use in companion animals so much of the data
generated for a food producing animal that would accelerate any
human health program would not be readily available.
The BZs represent a wide variety of molecules developed by
several animal health companies and launched mostly in the
1960’s and early 1970’s for livestock, horses and companion
animals. As mentioned above, albendazole and mebendazole are
the most widely used drugs against STH today. The BZs act as
inhibitors of tubulin formation, affecting cell synthesis and function
[18,19]. The main disadvantage is that, as a class, the BZs are
teratogens in animals and are contraindicated for use in the first
trimester of pregnancy. Additionally, there is concern that their
widespread use in public health programmes in highly endemic
countries will result in helminth resistance, just as seen in the
veterinary field a few years after their introduction. Before
selecting any of the other BZs identified (fenbendazole, flubenda-
zole, oxfendazole, oxibendazole, thiabendazole and netobimin) for
development for STHs, any advantage over albendazole or
mebendazole in terms of potential cross-resistance, improved
efficacy profile or contraindications, would have to carefully
considered. For example, fenbendazole given at doses of 30–
50 mg/kg only achieved a cure rate of 28.6% in 28 Korean
patients with T. trichiura respectively [20]. Finally, oxfendazole and
flubendazole are currently being investigated for treatment of
systemic helminth infections in humans by the NIH and BMGF,
and no publicly available information in humans exists for
oxibendazole, which had been in clinical development for STH
by SmithKlineBeecham/GlaxoSmithKline until about 2003.
Paraherquamide A is a natural product produced by Penicillium
paraherquei which was discovered in 1981 [21]. It was evaluated by
Merck in the late 1980’s and a small chemistry effort was
conducted to produce analogs [22]. Paraherquamide A was found
to have outstanding broad spectrum nematocidal activity against
various sheep gastro-intestinal nematodes [23]. It is a nicotinic
antagonist that blocks depolarization in muscles and induces a
rapid paralysis of the mid-body of the parasite [24]. However, it
was severely toxic in mice and dogs, which prevented its
development [25], as these species are the standard models for
safety studies. In addition, poor activity was observed against T.
vulpis in dogs [25]. UpJohn, later Pfizer, conducted semi-synthetic
medicinal chemistry on Paraherquamide A [26] and eventually
identified derquantel as a safer but still effective compound against
sheep gastrointestinal parasites. Derquantel was noted, however,
to cause lethality in horses [27] and was not pursued for this
species. This product is being developed as a sheep product in
Australia and New Zealand in combination with abamectin [28].
It remains to be confirmed whether derquantel offers improved
efficacy against Trichuris spp. In addition, a thorough evaluation of
potential toxicity of derquantel or any metabolites will have to be
done prior to any administration to humans, acknowledging the
history of this compound class. This issue lowered the priority for
this compound in our evaluation.
No new compounds were identified within the hexahydropyr-
azine and imidazothiazole classes. Many of the hexahydropyr-
azines (DEC, piperazine, praziquantel and epsiprantel) and the
imidazothiazole levamisole have been used for many years in
Drug Development Candidates for STH
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neuromuscular blocking agents, such as pyrantel, has been used
for decades in human health [8,29], and the related molecule
morantel would not offer any advantage over pyrantel.
Amidantel (BAY d 8815), a precursor of tribendimidine, was
evaluated by Bayer in late 1970’s. It showed efficacy against
hookworms and ascarids in dogs with a single oral dose of 25 mg/
kg [30], including Toxacara canis, which was completely eliminated
by a single 10 mg/kg oral treatment. Early studies showed the
compound acted as an acetylcholine agonist [31]. The compound
was not marketed as a veterinary product as the drug had to be
given twice on two consecutive days, which was a great
disadvantage in the face of other existing anthelmintics for
companion animals [32]. As tribendimidine, a symmetrical
diamidine derivative of amidantel, is marketed in China for
STH [33] and being pursued for human use, amidantel was not
considered as a candidate from our analysis.
The salicylanilides (closantel, niclosamide, oxyclozanide, rafox-
anide), the phenylsulfonamide clorsulon, the biphenylsulfides
bithionol and febantel, and nitroscanate and nitroxynil are
structurally similar with all containing one or more phenyl groups
with halide or phenolic hydroxyls and/or nitro group substitu-
tions. They are among the older anthelmintics developed for
veterinary medicine and are still used, although safer and broader
spectrum parasiticides take precedence except where price is more
of a priority. They generally act as uncouplers of oxidative
phosphorylation and so would not be prime candidates for human
development without a thorough toxicology evaluation. In
Table 1. Summary of approved veterinary anthelmintics.
Compound class Drug (example) Current supplier Efficacy Safety and toxicity
Avermectin Ivermectin Merial, Ltd Broad spectrum nematocide
including immature filarial worms
Wide safety margin at use level; no
reproductive safety issues
Milbemycin Moxidectin Pfizer Broad spectrum nematocide including
immature filarial worms
Wide safety margin at use level; no
reproductive safety issues
Benzimidazoles Albendazole GSK Broad spectrum anthelmintic;
widespread resistance amongst
veterinary parasites
Generally safe but teratology
issues known in the compound
class in first trimester
Depsipeptide Emodepside Bayer Approved for ascarids and
hookworms in cats
Wide safety margin with approved
drug
Paraherquamide Derquantel Pfizer Most GI nematodes in sheep
and active against those resistant to
other nematocides
Derquantel is an approved
veterinary drug, but
paraherquamide A is quite toxic in
dogs and mice
Hexahydroxy-pyrazines DEC Generic Anti-filarial: immature stages Contraindicated for dogs infected
with heartworm
Piperazine Dow Ascarids (birds and swine) and
Oesophagostomum spp. in swine
Safe drug; oral rat LD50 1900 mg/
kg
Praziquantel Bayer Tapeworms, broad spectrum
trematocidal activity except
Fasciola spp.
Wide safety margin at use level;
safe for use in pregnant dogs
Tetrahydro-pyrimidines Pyrantel pamoate Pfizer Ascarids and hookworms in dogs;
GI nematodes in horses
Wide safety margin at use level; no
reproductive safety issues
Imidazo-thiazoles Levamisole Janssen Broad spectrum nematocide, excluding
filarial worms;
widespread resistance amongst
sheep abomasal parasites
Wide safety margin at use level; no
reproductive safety issues
Amino-aceto-nitriles Monepantel Novartis Broad spectrum activity against
sheep GI nematodes
No contraindications and no
reproductive effects observed in
rats or rabbits
Salicylanilides Closantel Janssen Sheep liver fluke and Haemonchus
contortus
Only for use in male sheep,
overdose might cause blindness
Rafoxanide Merial, Ltd Cattle, sheep liver fluke and GI
nematodes
Some teratology noted in safety
studies in rats and rabbits
Phenyl-sulfonamide Clorsulon Merial, Ltd Cattle adult and immature liver fluke Wide safety margin
Biphenylsulfides Bithionol Monsanto Rumen and liver flukes, tapeworm Sulfoxide form toxic at 280 mg/kg.
Contraindicated for animals with
renal disease
Febantel Bayer Canine intestinal tract nematodes
including Trichuris vulpis
Potentially teratogen in first
trimester as pro-benzimidazole
Miscellaneous Nitroscanate Novartis Canine intestinal nematodes Safe to give to pregnant animals;
can cause vomiting in some dogs
on dosing
Nitroxynil Generic Cattle and sheep flukes and
limited GI nematode spectrum
No safety issues reported
doi:10.1371/journal.pntd.0001138.t001
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rafoxanide) are only active against the trematode Fasciola hepatica
[34,35] and do not possess nematocidal activity.
Hence, from our initial assessment we selected 4 compounds,
which fulfilled further progression criteria (no cross resistance to
already available drugs, excellent activity and toxicity profile).
These four drugs are already marketed for either human
(nitazoxanide, tribendimidine) or veterinary (the depsipeptide,
emodepside and the aminoacetonitrile, monepantel) use. We did
not compile a dossier on tribendimidine, which is registered for
human use in China and is being developed for regulatory
approval by a consortium composed of XPC China, Swiss
Tropical and Public Health Institute (Swiss TPH), and Institute
for One World Health (iOWH.) The structures of emodepside,
monepantel and nitazoxanide are depicted in Figure 1.
Drug profiles of emodepside, monepantel and
nitazoxanide
Information was available through documentation in the EMA
and FDA registration files (EPAR and FOI summaries, respec-
tively) and from available Material Safety Data Sheets as well as
scientific publications. Complete dossiers with these data are
provided as supplementary data and a brief summary of each of
the drugs is provided below. The physico-chemical characteristics
of these compounds are summarized in Appendix S3.
Emodepside
Emodepside is a semi-synthetic derivative of the cyclooctadep-
sipeptide PF1022A, a natural product compound produced by
fermentation of the fungus Mycelia sterilia [36]. Anthelmintic
activities of emodepside have been demonstrated in several in vitro
and in vivo studies against various nematodes [37,38]. Bayer
Animal Health developed emodepside for use in cats and
registered a topically administered product in combination with
praziquantel to treat hookworms and ascarids (emodepside) and
tapeworms (praziquantel) in Europe in 2005 and in the U.S. in
2007. The compound has a unique dual mechanism of action at
the neuromuscular junction that involves on the one hand binding
to a presynaptic latrophilin-like receptor and on the other hand
pre- and post-synaptic interactions with a Ca
2+-activated K
+ ion
channel (SLO-1). Binding of emodepside to the latrophilin
receptor and the SLO-1 ion channel in the parasite leads to
inhibition of pharyngeal pumping, paralysis and death [39,40].
Emodepside appears to be of low general toxicity and exhibits no
genotoxic properties. Although some adverse effects were noted in
embryotoxicity/teratogenicity studies in rats and rabbits, the use of
the compound in pregnant cats has not been associated with any
teratogenic findings. This compound represents a new class of
anthelmintic, which could potentially be useful to treat helmin-
thiasis in humans. The primary issue will be cost and to our
knowledge, no studies have been published to date on the efficacy
of the drug against specific soil-transmitted helminths (For detailed
information see Appendix 4). In addition, some safety aspects
(notably safety pharmacology, reproductive toxicity and neuro-
toxicity) remain to be elucidated. Of note, PF1022A, the
emodepside precursor should also be considered, since the drug
has a broad spectrum of activity [38,41] and might have lower
production costs.
Monepantel
The amino-acetonitrile derivatives (AAD) represent a novel
class of anthelmintic drugs developed by Novartis Animal Health
for use in sheep and potentially in cattle [42]. Monepantel, a
member of this family, was registered in New Zealand as ZolvixH
in 2009 for sheep abomasal parasites (Haemonchus contortus,
Trichostrongylus colubriformis, and Teladorsagia circumcincta) and certain
intestinal parasites (Oesphagostomum spp., Nematodirus spp., and
Chabertia spp. but not T. ovis). As of January 2011 the product has
been registered in a total of 32 countries in Australasia, Europe
and Latin America. It is an agonist of a helminth-specific
subfamily (DEG-3) of the nicotinic acetylcholine receptor,
specifically attacking its subunit Hco-MPTL-1. Activation of the
receptor through this agonist action causes hyper-contraction of
the parasite body and spasmodic contraction of the pharynx [43].
It has been reported to be effective against veterinary parasites
resistant to known anthelmintics including macrocylic lactones,
benzimidazoles and levamisole [43], a characteristic which could
potentially give it an advantage as a human health drug. As the
product was just recently launched there has been no field
resistance reported as yet. It has recently been demonstrated that
monepantel is not active against Strongyloides ratti in vitro, which
lacks such a MPTL-1 homolog [44]. A complete program of safety
pharmacology and toxicology studies has been conducted. The
compound appears to be of adequate safety with only adaptive
effects noted in general toxicity studies and with no adverse effects
in reproductive toxicity (paternal and embryo-foetal) observed in
different animal species [45,46]. Monepantel is also without
Figure 1. Chemical structures of emodepside, monepantel and nitazoxanide.
doi:10.1371/journal.pntd.0001138.g001
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clean safety profile and is reportedly not contraindicated in
pregnancy; (ii) is not cross-resistant with the BZ family; and (iii) has
a contemporary state-of-the-art regulatory dossier for veterinary
use. The efficacy of the drug against some of the soil-transmitted
helminths is not yet known. Specifically, there is no information on
its activity on Necator americanus and Trichuris trichiura. Since the
genomes of these two species are not published yet, and since
predicting sensitivity on the basis of genomic information (such as
whether the receptors conferring sensitivity to monepantel are
present in Trichuris) might be inaccurate or insufficient, in vitro and
in vivo experiments will be needed to complete its efficacy profile.
Hence, we have started in vitro and in vivo studies with monepantel
against T. muris and hookworms in our laboratories. For detailed
information on monepantel see Appendix S5.
Nitazoxanide
Nitazoxanide is an antiprotozoal drug used for the treatment of
infections with Cryptosporidiumparvumand Giardiaintestinalis.Thedrug
(trade name: AliniaH) is commonly given in six divided doses
(500 mg bid for 3 days for adults and 200 mg bid for 3 days for
children aged 4–11 years). The safety and tolerability of
nitazoxanide in humans has been documented by .10 years of
commercial use, during which more than 20 million people have
been treated with this drug (Romark Laboratories, pers. commun.),
most of them for relatively short durations ranging from 3 to 10
days. Three studies carried out in Mexico have shown that
nitazoxanide achieved high cure rates against T. trichiura and A.
lumbricoides [48–50]. For example, in Mexico cure rates of 78 and
56% were achieved against light and moderate infections with T.
trichiura [48]. However, studies against hookworms and using single
doses remain to be done. Its mode of action involves inhibition of
enzymes relevant for the survival of the parasites in an anaerobic
environment, such as pyruvate:ferredoxin/flavodoxin oxidoreduc-
tases, nitroreductases and/or protein disulphide isomerases. Nita-
zoxanide appears to be a drug with no major safety issues emerging
from non-clinical safety pharmacology and toxicology studies.
Specifically, reproductive toxicity was not significantly affected due
to the low absorption from the gastrointestinal tract, thus allowing
its use in pregnancy. Although the haematotoxicity observed in rats
and dogs might warrant special consideration for the use of
nitazoxanide in G6PD-deficient patients, there was no evidence
from the post-marketing experience for any major safety problems
associated with the human use of nitazoxanide at recommended
doses. For detailed information see Appendix S6.
Discussion
The main objective of this work was to identify potential drug
candidates that would be eligible for rapid transitioning into
development for human STH infections. We have not considered
possible drug combinations in the present work, as this strategy has
already been discussed in recent reviews [7].
Several elements have to be taken into consideration when
deciding whether a compound deserves further investigation and
before investment is made to provide sufficient data for an informed
development track decision. Examples are: cost of goods, suitability
offormulationforhumanuse,additionalnon-clinicalpharmacology
data such as efficacy against the target human helminths, safety,
including potential drug:drug interactions, and pharmacology.
Many of these issues have yet to be addressed in detail and may
result in further reduction in the already sparse list of candidates.
Itisclearfromthesesearchesthat the majorityofcompoundsthat
could be developed still come from animal health. While this
analysis has focussed on single drug candidates, it is important to
recognise that there may not be one simple solution to the problem,
especially since humans, like their animal counterparts, may be
infected with several species of helminth at one time. Thus drugs
may be identified that, taken together in combination, may also
enhance efficacy and also reduce the risk of generating resistance.
This strategy is followed in the chemotherapy of HIV, tuberculosis
and malaria, and there is no reason to suppose that it would not also
be effective for STHs. Indeed, for example a recent study has shown
that a combination of mebendazole and ivermectin has enhanced
efficacy against trichuriasis, while protecting from the poor efficacy
of ivermectin against hookworm [51].
Although drugs registered for animal health could be rapidly
transitioned into humans, it is essential to conduct discussions with
the relevant regulatory authorities to ensure that all the necessary
pre-clinical studies have been or can be conducted to permit
human studies. The examination of data compiled in analyses such
as presented here, together with expertise on regulatory process,
should enable to identify the most suitable candidates, requiring
the lowest progression investment. While this can accelerate the
transition into humans, it should also be recognised that the most
expensive phase of development is yet to be faced, and not all
potential candidates will make it through human efficacy testing.
Finally, it is one thing to register a drug (difficult though it may
be), but getting it into use is a challenge of a different level of
complexity, especially in the case of STH or other helminthic
diseases. Here, the product is not chosen by the individual customer
or prescriber, but is rather selected by control programmes or even
internationally for procurement and distribution through MDA.
With all theirlimitations, displacing the current BZswill be complex
even for a very good drug. After all, BZs are capable of reducing
infection intensity (and thus morbidity), are generally safe, are given
in a single dose and the same dose for all, and are donated to a large
extent. Cost-effectiveness will be an issue and will include
consideration of the cost of changing policy as well, against the
prospective advantages of the new drug.
We believe it was important both to conduct this analysis and to
share and make the results publicly available. STH and
helminthiasis in general are among the most neglected diseases
in terms of drug R&D, even compared to other tropical diseases,
such as those caused by kinetoplastids (leishmaniasis, African
trypanosomiasis, Chagas disease) or malaria [52]. Today there are
few dedicated funds for anthelmintic, particularly STH, R&D for
human use; there are some potential but scattered initiatives and
little or no cohesive approach thus far. With scarce resources, and
the high costs and long development times for new drugs,
developing the wrong candidate or a ‘‘me-too’’ drug (drugs that
will offer no significant public health advantage over existing
interventions) is not an option.
Making the results of this search publicly available will hopefully
assist decision making for R&D in the community of developers
and funders. However, this will only be the beginning, as more
needs to be done. Based on our assessment, we will endeavour to
access proprietary information through confidentiality agreements
with the respective companies and to generate the data that we feel
will be required to make a development track decision.
R e c e n t ly ,T D R ,B I OV e n t u r e sf o rGl o b a lH e a l t h( B V G H)a n dt h e
Sabin Vaccine Institute initiated discussions with a number of public
and not-for-profit organizations potentially interested in drug
development for helminths including developers, researchers and
funding agencies. The objective is to favour an enabling environment
for anthelmintic R&D, consistency and openness (with sharing of
information). Hopefully a degree of cohesion can be reached. In the
case of STH (and helminths at large) R&D, the situation is such (little
Drug Development Candidates for STH
www.plosntds.org 6 June 2011 | Volume 5 | Issue 6 | e1138resources, few candidate drugs, few development partners) that it
must be approached considering the global R&D pipeline rather than
individual initiatives by single organizations. This will hopefully
provide consistency and consolidate development efforts. And this is
the spirit underlying this paper.
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